Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.5K
Drug Regulation01:25

Drug Regulation

2.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.5K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

108
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
108
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

123
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
123
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications.

Toxicologic pathology·2026
Same author

Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease".

Journal of medicinal chemistry·2026
Same author

Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

Journal of medicinal chemistry·2026
Same author

Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data.

Regulatory toxicology and pharmacology : RTP·2026
Same author

HESI GTTC ring trial: Concordance between Ames and rodent carcinogenicity outcomes for N-nitrosamines (NAs) with rat and hamster metabolic conditions.

Regulatory toxicology and pharmacology : RTP·2025
Same author

Response to reader comment on: "Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir".

Toxicological sciences : an official journal of the Society of Toxicology·2024

Related Experiment Video

Updated: Nov 25, 2025

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.2K

Development and Regulatory Challenges for Peptide Therapeutics.

Doris Zane1, Paul L Feldman2, Tomi Sawyer3

  • 1435529Intarcia Therapeutics, Inc., Hayward, CA, USA.

International Journal of Toxicology
|December 17, 2020
PubMed
Summary

Peptide therapeutics show promise for treating diseases, but challenges remain in development and delivery. Regulatory guidance interpretation for synthetic and conjugated peptides needs clarification for both industry and regulators.

Keywords:
drug discoverygenotoxicityimpuritiespeptideregulatory

More Related Videos

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.7K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.7K

Related Experiment Videos

Last Updated: Nov 25, 2025

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.2K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.7K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.7K

Area of Science:

  • Pharmacology and Toxicology
  • Drug Development
  • Regulatory Science

Background:

  • Peptide therapeutics are increasingly utilized for various human diseases.
  • Significant growth in peptide drug development faces challenges in discovery, optimization, delivery, and regulatory pathways.
  • Disparities in applying existing regulatory guidelines to novel peptide assets create hurdles for sponsors and regulators.

Purpose of the Study:

  • To address the development and regulatory challenges of peptide therapeutics.
  • To explore advancements in discovering, optimizing, assessing, and delivering combination peptide therapeutics.
  • To discuss toxicological, regulatory, and genotoxicity testing considerations for peptide drug-device combination products and synthetic/conjugated peptides.

Main Methods:

  • A symposium was held at the 40th Annual Meeting of the American College of Toxicology.
  • Discussions focused on industry and regulatory perspectives on peptide therapeutic development and regulation.
  • Key topics included regulatory classifications, International Council for Harmonisation (ICH) guidances (M3(R2), S6(R1)), and genotoxicity testing.

Main Results:

  • Identified challenges in the interpretation and application of regulatory guidances for peptide therapeutics.
  • Highlighted the need for clear toxicological and nonclinical study recommendations for peptide drug-device combinations and synthetic/conjugated peptides.
  • Presented perspectives on genotoxicity testing requirements for peptide products.

Conclusions:

  • Clarification of regulatory pathways is crucial for advancing peptide therapeutics.
  • Harmonized interpretation of guidances like ICH M3(R2) and ICH S6(R1) is needed for efficient development.
  • Further dialogue between industry and regulatory bodies is essential to overcome challenges in peptide therapeutic development and patient delivery.